ImmunityBio Inc. Common Stock vs SpaceX — how do they compare? ImmunityBio Inc. Common Stock trades at $10.03 (market cap $10.51B), while SpaceX trades at $165.79 (market cap $2.18T). The key difference: SpaceX is far larger — about 207.4× ImmunityBio Inc. Common Stock's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, SpaceX nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and SpaceX for 41 Days on average.
| IBRX | SPCX | |
|---|---|---|
Market Cap | $10.51B | $2.18T |
Volume | 10,445,785 | 68,508,567 |
Sector | Health | Industrials |
52-Week High | $11.55 | $202.09 |
52-Week Low | $1.98 | $108.27 |
Typical Hold Time | 0 Days | 41 Days |
Enterprise Value | $10.97B | $2.12T |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →SpaceX is the world's leading aerospace manufacturer and launch provider. It designs and operates reusable rockets, spacecraft, and Starlink, a global satellite internet service with over 10 million subscribers across 160 countries.
Read more on SPCX →